Is ALGN a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Align Technology (ALGN) rests on Clear-aligner market penetration: Clear aligners still represent a minority of the roughly 500 million people worldwide with malocclusion, leaving a long runway as treatment shifts away from metal braces. Revenue (FY2025) is ~$4.0B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness. Whether ALGN is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Align Technology is a global medical device company best known for Invisalign, the clear-aligner system that has become the dominant alternative to traditional metal braces, and for iTero, its line of intraoral scanners used to capture digital impressions and plan treatment. The business splits into two segments: Clear Aligner, which generated roughly $3.2 billion of Align's approximately $4.0 billion in fiscal 2025 revenue, and Imaging Systems and CAD/CAM services (iTero and exocad software), which added about $0.8 billion. Align sells primarily through orthodontists and general dentists, and its scanners feed cases directly into the Invisalign workflow, creating a self-reinforcing ecosystem. The investment picture is a high-quality franchise navigating a maturing growth phase. Align holds a leading share of a large, still-underpenetrated clear-aligner market with strong brand recognition and high gross margins near 70 percent, but revenue growth has slowed to low single digits as North America matures and lower-priced rivals expand. Recent results show renewed volume momentum internationally, and the company continues to return cash through buybacks. Because the stock trades at a premium earnings multiple, the debate centers on whether Align can convert its ecosystem advantage and international runway into faster growth while defending pricing.
What's the case for buying ALGN?
1. Clear-aligner market penetration
Clear aligners still represent a minority of the roughly 500 million people worldwide with malocclusion, leaving a long runway as treatment shifts away from metal braces. Align's brand, doctor relationships, and case-management software position it to capture a meaningful share of that expansion. Growth in EMEA, APAC, and Latin America has been running at double-digit rates, offsetting a more mature North America.
2. iTero scanner and digital ecosystem
The iTero scanner line and exocad CAD/CAM software lock doctors into Align's digital workflow, with the majority of Invisalign cases now submitted through digital scans. This razor-and-blade dynamic drives recurring aligner volume and switching costs. New scanner models and AI-assisted treatment tools aim to deepen that ecosystem advantage.
3. Margin profile and capital returns
Align operates with gross margins near 70 percent and generates substantial free cash flow, which it has been directing toward share repurchases, including a fresh $200 million authorization announced in early 2026. Manufacturing scale in lower-cost regions supports profitability. Disciplined cost management gives the company flexibility to invest in growth while returning cash.
4. Adult and teen segment expansion
Align continues to broaden its addressable base, with growth in adult patients seeking discreet treatment and in teens and younger patients where clear aligners are displacing braces. Product features aimed at complex cases expand the range of treatments aligners can address. Direct-to-consumer marketing and doctor-education programs support demand across both cohorts.
What are the risks to ALGN?
Growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness. Competition is intensifying from lower-priced systems such as Straumann's ClearCorrect, Dentsply Sirona's SureSmile, and Envista's Spark, which can pressure both volume and pricing. Align manufactures aligners in Mexico and ships them to the United States, exposing it to tariff and trade-policy shifts, and a large portion of revenue is international, adding foreign-exchange sensitivity. The premium valuation leaves little room for disappointment, so a growth stumble can drive an outsized share reaction. Patent expirations over time may further lower barriers to entry for competitors.
How is ALGN valued? (as of July 2026)
Snapshot for ALGN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY2025): ~$4.0B
- Revenue (Q1 2026): ~$1.04B, up ~6% YoY
- Q1 2026 EPS: ~$1.57
- Gross margin: ~71%
- Market cap: ~$13B
- P/E ratio: ~30x
As of July 2026, Align posted roughly $4.0 billion in fiscal 2025 revenue and around $1.04 billion in the first quarter of 2026, up about 6 percent year over year with record Invisalign shipments. The stock trades near a market capitalization of $13 billion at a price-to-earnings multiple around 30 times, a premium that reflects the company's leadership and margins but also assumes a return to healthier growth. The company reaffirmed its 2026 guidance and authorized a new $200 million buyback.
How do you decide if ALGN is a buy?
Rather than asking whether ALGN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ALGN indirectly through an index or sector ETF before adding more.
For the full picture, see the ALGN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ALGN against your real portfolio and see your actual exposure before deciding.
The bottom line on ALGN
The bottom line: Align Technology's story right now is Clear-aligner market penetration, with revenue (fy2025) at ~$4.0B. If you believe that narrative continues, the call is about sizing ALGN sensibly and checking overlap with what you own; if you doubt it (the risk: growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ALGN with Walnut
Use Align Technology as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ALGN a good stock to buy right now?
+
The case for Align Technology right now is Clear-aligner market penetration, with revenue (fy2025) at ~$4.0B. If you believe that thesis holds, ALGN is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Align Technology do?
+
Align Technology is a global medical device company best known for Invisalign, the clear-aligner system that has become the dominant alternative to traditional metal braces, and fo
What are the main risks of ALGN?
+
Growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness. Competition is intensifying from lower-priced systems such as Straumann's ClearCorrect, Dentsply Sirona's SureSmile, and Envista's Spark, which can pressure both volume and pricing. Align manufactures aligners in Mexico and ships them to the United States, exposing it to tariff and trade-policy shifts, and a large portion of revenue is international, adding foreign-exchange sensitivity. The premium valuation leaves little room for disappointment, so a growth stumble can drive an outsized share reaction. Patent expirations over time may further lower barriers to entry for competitors.
What does Align Technology do?
+
Align Technology makes Invisalign clear aligners, which straighten teeth as a discreet alternative to metal braces, and iTero intraoral scanners plus exocad software used by dentists and orthodontists to capture digital impressions and plan treatment. Clear aligners are the large majority of its revenue.
How does Align make money?
+
Most revenue comes from selling Invisalign aligners to orthodontists and general dentists, who treat patients. A smaller but meaningful share comes from selling iTero scanners and CAD/CAM software, which feed cases back into the aligner business and create recurring demand.
How big is Align Technology?
+
As of July 2026, Align generated roughly $4.0 billion in fiscal 2025 revenue and carried a market capitalization near $13 billion, making it one of the larger companies in the medical device and dental equipment space.
Is Align Technology profitable?
+
Yes. Align operates with gross margins near 70 percent and reported net income of about $113 million and earnings per share around $1.57 in the first quarter of 2026, generating substantial free cash flow that funds share buybacks.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ALGN; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.